3 days Is Bristol Myers Squibb Stock a Buy?The Motley Fool
It’s been a challenging past few years for Bristol Myers Squibb (NYSE: BMY). The company’s financial results dipped following the loss of patent exclusivity of two important medicines in its arsenal: cancer drugs Revlimid (its former top-selling produc…
Bristol · Bristol-Myers Squibb (BMY) · NYSE
X